{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:55:22Z","timestamp":1791903322466,"version":"4.3.4"},"reference-count":100,"publisher":"American Society of Hematology","issue":"19","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,10,13]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>The role of thrombophilia in clinical decision-making regarding secondary venous thromboembolism (VTE) prevention is still uncertain. Therefore, we aimed to investigate the association between hereditary and acquired thrombophilia and recurrent VTE after discontinuation of anticoagulation after initial VTE treatment. We conducted a systematic review and meta-analysis to evaluate the risk of recurrent VTE in patients with and without thrombophilia including factor V Leiden (FVL) mutation, prothrombin gene G20210A mutation (PTM), antithrombin deficiency (ATD), protein C deficiency (PCD), protein S deficiency (PSD), and antiphospholipid antibody syndrome (APS). Eligible studies included randomized trials and cohort studies reporting recurrent VTE after discontinuation of anticoagulation after completion of VTE treatment. Study-level incidence rates (IR) per 100 patient-years, IR ratios, and adjusted hazard ratio were calculated or extracted and pooled using random-effects models. Certainty of evidence was assessed using the Grading of Recommendations, Assessment, Development, and Evaluation approach. A total of 51 studies (n = 34\u2009623 patients; 42.3% female; 33.5% with unprovoked index VTE) were included. Thrombophilias, including APS, ATD, homozygous FVL, and compound heterozygous FVL\/PTM, were associated with an approximately twofold to threefold increased risk of recurrent VTE, whereas heterozygous FVL or PTM mutations were associated with a 1.5-fold increased risk. Heterogeneity and the certainty in the evidence were predominantly moderate. Evidence regarding PSD and PCD was inconclusive. Both hereditary and acquired thrombophilia are associated with an increased risk of recurrent VTE after discontinuation of anticoagulation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/bloodadvances.2026020623","type":"journal-article","created":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T23:30:36Z","timestamp":1784071836000},"page":"6331-6345","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Recurrent VTE in patients with thrombophilia after stopping anticoagulation: a systematic review and meta-analysis"],"prefix":"10.1182","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1381-4858","authenticated-orcid":false,"given":"Kristina","family":"Vrotniakaite-Bajerciene","sequence":"first","affiliation":[{"name":"1Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"},{"name":"2Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2407-9000","authenticated-orcid":false,"given":"Tzu-Fei","family":"Wang","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elham","family":"Sabri","sequence":"additional","affiliation":[{"name":"3Ottawa Hospital Methods Center, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0388-5812","authenticated-orcid":false,"given":"Risa","family":"Shorr","sequence":"additional","affiliation":[{"name":"4Information Services, The Ottawa Hospital, Ottawa, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2872-4863","authenticated-orcid":false,"given":"Anne","family":"Angelillo-Scherrer","sequence":"additional","affiliation":[{"name":"1Department of Hematology and Central Hematology Laboratory, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gr\u00e9goire","family":"Le Gal","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marc","family":"Carrier","sequence":"additional","affiliation":[{"name":"2Department of Medicine, Ottawa Hospital Research Institute, University of Ottawa, Ottawa, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2026,9,23]]},"reference":[{"issue":"8","key":"2026101310433973900_bib1","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrcardio.2015.83","article-title":"Epidemiology of venous thromboembolism","volume":"12","author":"Heit","year":"2015","journal-title":"Nat Rev Cardiol"},{"issue":"21","key":"2026101310433973900_bib2","doi-asserted-by":"crossref","first-page":"11447","DOI":"10.3390\/ijms252111447","article-title":"The basic principles of pathophysiology of venous thrombosis","volume":"25","author":"Schulman","year":"2024","journal-title":"Int J Mol Sci"},{"issue":"21","key":"2026101310433973900_bib3","doi-asserted-by":"crossref","first-page":"3081","DOI":"10.1182\/bloodadvances.2018020230","article-title":"Who should get long-term anticoagulant therapy for venous thromboembolism and with what?","volume":"2","author":"Rodger","year":"2018","journal-title":"Blood Adv"},{"issue":"4","key":"2026101310433973900_bib4","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1093\/eurheartj\/ehz405","article-title":"2019 ESC guidelines for the diagnosis and management of acute pulmonary embolism developed in collaboration with the European Respiratory Society (ERS)","volume":"41","author":"Konstantinides","year":"2020","journal-title":"Eur Heart J"},{"issue":"7","key":"2026101310433973900_bib5","doi-asserted-by":"crossref","first-page":"1480","DOI":"10.1111\/jth.13336","article-title":"Categorization of patients as having provoked or unprovoked venous thromboembolism: guidance from the SSC of ISTH","volume":"14","author":"Kearon","year":"2016","journal-title":"J Thromb Haemost"},{"issue":"19","key":"2026101310433973900_bib6","doi-asserted-by":"crossref","first-page":"4693","DOI":"10.1182\/bloodadvances.2020001830","article-title":"American Society of Hematology 2020 guidelines for management of venous thromboembolism: treatment of deep vein thrombosis and pulmonary embolism","volume":"4","author":"Ortel","year":"2020","journal-title":"Blood Adv"},{"issue":"12","key":"2026101310433973900_bib7","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1056\/NEJMra1700365","article-title":"Thrombophilia testing and venous thrombosis","volume":"377","author":"Connors","year":"2017","journal-title":"N Engl J Med"},{"issue":"4","key":"2026101310433973900_bib8","doi-asserted-by":"crossref","first-page":"907","DOI":"10.1016\/j.mcna.2025.01.008","article-title":"Thrombophilia testing in venous thromboembolism","volume":"109","author":"Vrotniakaite-Bajerciene","year":"2025","journal-title":"Med Clin North Am"},{"key":"2026101310433973900_bib9","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.thromres.2022.12.001","article-title":"Adherence to thrombophilia testing guidelines and its influence on anticoagulation therapy: a single-center cross-sectional study","volume":"223","author":"Vrotniakaite-Bajerciene","year":"2023","journal-title":"Thromb Res"},{"issue":"14","key":"2026101310433973900_bib10","doi-asserted-by":"crossref","first-page":"4188","DOI":"10.3390\/jcm11144188","article-title":"Thrombophilia impact on treatment decisions, subsequent venous or arterial thrombosis and pregnancy-related morbidity: a retrospective single-center cohort study","volume":"11","author":"Vrotniakaite-Bajerciene","year":"2022","journal-title":"J Clin Med"},{"issue":"suppl 1","key":"2026101310433973900_bib11","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/ijlh.12672","article-title":"Optimal utilization of thrombophilia testing","volume":"39","author":"Pruthi","year":"2017","journal-title":"Int J Lab Hematol"},{"issue":"2","key":"2026101310433973900_bib12","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1007\/s11239-025-03183-2","article-title":"Clinical utility and costs of inpatient hereditary thrombophilia testing following acute VTE: a 5-year retrospective study","volume":"59","author":"Munda","year":"2026","journal-title":"J Thromb Thrombolysis"},{"issue":"12","key":"2026101310433973900_bib13","first-page":"Cd007069","article-title":"Thrombophilia testing for prevention of recurrent venous thromboembolism","volume":"12","author":"Cohn","year":"2012","journal-title":"Cochrane Database Syst Rev"},{"issue":"7","key":"2026101310433973900_bib14","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1001\/archinte.166.7.729","article-title":"Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review","volume":"166","author":"Ho","year":"2006","journal-title":"Arch Intern Med"},{"issue":"8","key":"2026101310433973900_bib15","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.3324\/haematol.10234","article-title":"The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies","volume":"92","author":"Marchiori","year":"2007","journal-title":"Haematologica"},{"key":"2026101310433973900_bib16","doi-asserted-by":"crossref","first-page":"883986","DOI":"10.3389\/fcvm.2022.883986","article-title":"Current knowledge on factor V Leiden mutation as a risk factor for recurrent venous thromboembolism: a systematic review and meta-analysis","volume":"9","author":"Eppenberger","year":"2022","journal-title":"Front Cardiovasc Med"},{"issue":"23","key":"2026101310433973900_bib17","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.1001\/jama.2009.853","article-title":"Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review","volume":"301","author":"Segal","year":"2009","journal-title":"Jama"},{"issue":"4","key":"2026101310433973900_bib18","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1055\/s-0038-1625983","article-title":"Risk of venous thrombosis in antithrombin deficiency: a systematic review and Bayesian meta-analysis","volume":"44","author":"Croles","year":"2018","journal-title":"Semin Thromb Hemost"},{"issue":"10","key":"2026101310433973900_bib19","doi-asserted-by":"crossref","first-page":"4285","DOI":"10.1007\/s00277-024-05926-2","article-title":"Venous thromboembolism risk in adults with hereditary thrombophilia: a systematic review and meta-analysis","volume":"103","author":"Alnor","year":"2024","journal-title":"Ann Hematol"},{"issue":"5","key":"2026101310433973900_bib20","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1016\/j.thromres.2015.03.010","article-title":"Natural anticoagulants deficiency and the risk of venous thromboembolism: a meta-analysis of observational studies","volume":"135","author":"Di Minno","year":"2015","journal-title":"Thromb Res"},{"key":"2026101310433973900_bib21","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"2026101310433973900_bib22","doi-asserted-by":"crossref","first-page":"k4597","DOI":"10.1136\/bmj.k4597","article-title":"A guide to systematic review and meta-analysis of prognostic factor studies","volume":"364","author":"Riley","year":"2019","journal-title":"BMJ"},{"issue":"1","key":"2026101310433973900_bib24","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/jth.15109","article-title":"Recommendations for clinical laboratory testing for protein S deficiency: communication from the SSC committee plasma coagulation inhibitors of the ISTH","volume":"19","author":"Marlar","year":"2021","journal-title":"J Thromb Haemost"},{"issue":"7","key":"2026101310433973900_bib25","doi-asserted-by":"crossref","first-page":"1735","DOI":"10.1111\/jth.15732","article-title":"Diagnosis and management of severe congenital protein C deficiency (SCPCD): communication from the SSC of the ISTH","volume":"20","author":"Minford","year":"2022","journal-title":"J Thromb Haemost"},{"issue":"1","key":"2026101310433973900_bib26","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1111\/jth.14648","article-title":"Recommendations for clinical laboratory testing for antithrombin deficiency; communication from the SSC of the ISTH","volume":"18","author":"Van Cott","year":"2020","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2026101310433973900_bib27","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.jtha.2024.10.022","article-title":"An update on laboratory detection and interpretation of antiphospholipid antibodies for diagnosis of antiphospholipid syndrome: guidance from the ISTH-SSC Subcommittee on Lupus Anticoagulant\/Antiphospholipid Antibodies","volume":"23","author":"Devreese","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2026101310433973900_bib28","doi-asserted-by":"crossref","first-page":"280","DOI":"10.7326\/0003-4819-158-4-201302190-00009","article-title":"Assessing bias in studies of prognostic factors","volume":"158","author":"Hayden","year":"2013","journal-title":"Ann Intern Med"},{"issue":"1","key":"2026101310433973900_bib29","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1411","article-title":"Risk-of-bias VISualization (robvis): an R package and Shiny web app for visualizing risk-of-bias assessments","volume":"12","author":"McGuinness","year":"2021","journal-title":"Res Synth Methods"},{"key":"2026101310433973900_bib30","doi-asserted-by":"crossref","first-page":"101484","DOI":"10.1016\/j.cegh.2023.101484","article-title":"Introduction to the GRADE tool for rating certainty in evidence and recommendations","volume":"25","author":"Prasad","year":"2024","journal-title":"Clin Epidemiol Glob Health"},{"key":"2026101310433973900_bib31","volume-title":"GRADE Handbook for Grading Quality of Evidence and Strength of Recommendations. Updated October 2013","year":"2013"},{"issue":"1","key":"2026101310433973900_bib32","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/jrsm.1164","article-title":"Methods to estimate the between-study variance and its uncertainty in meta-analysis","volume":"7","author":"Veroniki","year":"2016","journal-title":"Res Synth Methods"},{"issue":"3","key":"2026101310433973900_bib33","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"issue":"10","key":"2026101310433973900_bib34","doi-asserted-by":"crossref","first-page":"2800","DOI":"10.1161\/01.CIR.92.10.2800","article-title":"Factor V Leiden and risks of recurrent idiopathic venous thromboembolism","volume":"92","author":"Ridker","year":"1995","journal-title":"Circulation"},{"issue":"4","key":"2026101310433973900_bib35","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1024\/0301-1526\/a000447","article-title":"Thrombophilia and risk of VTE recurrence according to the age at the time of first VTE manifestation","volume":"44","author":"Weingarz","year":"2015","journal-title":"Vasa"},{"issue":"1","key":"2026101310433973900_bib36","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1080\/10245332.2018.1535535","article-title":"Risk factors for venous thromboembolism (VTE) recurrences in Thai patients without cancer","volume":"24","author":"Satpanich","year":"2019","journal-title":"Hematology"},{"issue":"4","key":"2026101310433973900_bib37","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jvsv.2022.02.019","article-title":"Utility of hereditary thrombophilia testing among patients with lower extremity deep vein thrombosis","volume":"10","author":"Liu","year":"2022","journal-title":"J Vasc Surg Venous Lymphat Disord"},{"issue":"5","key":"2026101310433973900_bib38","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/j.contraception.2011.06.008","article-title":"Risk factors for recurrence of venous thromboembolism associated with the use of oral contraceptives","volume":"84","author":"Vaillant-Roussel","year":"2011","journal-title":"Contraception"},{"issue":"15","key":"2026101310433973900_bib39","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1161\/CIRCULATIONAHA.109.906347","article-title":"Risk of recurrent venous thrombosis in homozygous carriers and double heterozygous carriers of factor V Leiden and prothrombin G20210A","volume":"121","author":"Lijfering","year":"2010","journal-title":"Circulation"},{"issue":"6","key":"2026101310433973900_bib40","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1182\/blood-2008-08-174128","article-title":"Clinical relevance of decreased free protein S levels: results from a retrospective family cohort study involving 1143 relatives","volume":"113","author":"Lijfering","year":"2009","journal-title":"Blood"},{"issue":"1","key":"2026101310433973900_bib41","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1160\/TH08-06-0364","article-title":"High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin","volume":"101","author":"Brouwer","year":"2009","journal-title":"Thromb Haemost"},{"issue":"3","key":"2026101310433973900_bib42","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1007\/s11239-007-0059-z","article-title":"FV Leiden mutation and risk of recurrent venous thromboembolism in Serbian population","volume":"25","author":"Kovac","year":"2008","journal-title":"J Thromb Thrombolysis"},{"issue":"9","key":"2026101310433973900_bib43","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.3324\/haematol.10967","article-title":"Risk of recurrence after a first venous thromboembolic event in young women","volume":"92","author":"Laczkovics","year":"2007","journal-title":"Haematologica"},{"issue":"2","key":"2026101310433973900_bib44","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1055\/s-0038-1650249","article-title":"Probability of recurrence of thrombosis in patients with and without factor V Leiden","volume":"75","author":"Rintelen","year":"1996","journal-title":"Thromb Haemost"},{"issue":"5","key":"2026101310433973900_bib45","first-page":"695","article-title":"The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C and protein S","volume":"91","author":"De Stefano","year":"2006","journal-title":"Haematologica"},{"issue":"11","key":"2026101310433973900_bib46","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1056\/NEJM199909093411104","article-title":"The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation","volume":"341","author":"De Stefano","year":"1999","journal-title":"N Engl J Med"},{"issue":"1","key":"2026101310433973900_bib47","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1365-2141.2006.05960.x","article-title":"Risk of recurrent venous thromboembolism or bleeding in relation to thrombophilic risk factors in patients receiving ximelagatran or placebo for long-term secondary prevention of venous thromboembolism","volume":"133","author":"W\u00e5hlander","year":"2006","journal-title":"Br J Haematol"},{"issue":"4","key":"2026101310433973900_bib48","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.thromres.2004.12.012","article-title":"Thrombophilic abnormalities and recurrence of venous thromboembolism in patients treated with standardized anticoagulant treatment","volume":"116","author":"Santamaria","year":"2005","journal-title":"Thromb Res"},{"issue":"6","key":"2026101310433973900_bib49","first-page":"961","article-title":"Increased risk of recurrent venous thromboembolism during hormone replacement therapy--results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET)","volume":"84","author":"H\u00f8ibraaten","year":"2000","journal-title":"Thromb Haemost"},{"issue":"5","key":"2026101310433973900_bib50","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1046\/j.1538-7836.2004.00698.x","article-title":"Comparison of 1 month with 3 months of anticoagulation for a first episode of venous thromboembolism associated with a transient risk factor","volume":"2","author":"Kearon","year":"2004","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2026101310433973900_bib51","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1055\/s-0037-1614554","article-title":"The risk of recurrent venous thromboembolism in carriers and non-carriers of the G1691A allele in the coagulation factor V gene and the G20210A allele in the prothrombin gene. DURAC Trial Study Group. Duration of Anticoagulation","volume":"81","author":"Lindmarker","year":"1999","journal-title":"Thromb Haemost"},{"issue":"12","key":"2026101310433973900_bib52","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1056\/NEJM199903253401201","article-title":"A comparison of three months of anticoagulation with extended anticoagulation for a first episode of idiopathic venous thromboembolism","volume":"340","author":"Kearon","year":"1999","journal-title":"N Engl J Med"},{"issue":"4","key":"2026101310433973900_bib53","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/S0002-9343(98)00060-6","article-title":"Anticardiolipin antibodies predict early recurrence of thromboembolism and death among patients with venous thromboembolism following anticoagulant therapy. Duration of Anticoagulation Study Group","volume":"104","author":"Schulman","year":"1998","journal-title":"Am J Med"},{"issue":"4","key":"2026101310433973900_bib54","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1055\/s-0038-1656023","article-title":"The risk of recurrent venous thromboembolism in patients with and without factor V Leiden","volume":"77","author":"Eichinger","year":"1997","journal-title":"Thromb Haemost"},{"issue":"6","key":"2026101310433973900_bib55","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1056\/NEJM199702063360602","article-title":"The risk of recurrent venous thromboembolism in patients with an Arg506\u2192Gln mutation in the gene for factor V (factor V Leiden)","volume":"336","author":"Simioni","year":"1997","journal-title":"N Engl J Med"},{"issue":"1","key":"2026101310433973900_bib56","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/S0735-1097(00)01080-9","article-title":"G20210A mutation in the prothrombin gene and the risk of recurrent venous thromboembolism","volume":"37","author":"Miles","year":"2001","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"2026101310433973900_bib57","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/00001721-200309000-00002","article-title":"Is recurrent venous thromboembolism more frequent in homozygous patients for the factor V Leiden mutation than in heterozygous patients?","volume":"14","author":"Procare Group","year":"2003","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"9383","key":"2026101310433973900_bib58","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1016\/S0140-6736(03)14111-6","article-title":"Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study","volume":"362","author":"Baglin","year":"2003","journal-title":"Lancet"},{"issue":"3","key":"2026101310433973900_bib59","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1161\/01.CIR.0000079162.69615.0F","article-title":"Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia","volume":"108","author":"Palareti","year":"2003","journal-title":"Circulation"},{"issue":"5","key":"2026101310433973900_bib60","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1161\/01.CIR.0000137123.55051.9B","article-title":"Risk factors and recurrence rate of primary deep vein thrombosis of the upper extremities","volume":"110","author":"Martinelli","year":"2004","journal-title":"Circulation"},{"issue":"5","key":"2026101310433973900_bib61","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.ejvs.2005.05.038","article-title":"Genetic polymorphisms and risk of recurrent deep venous thrombosis in young people: prospective cohort study","volume":"30","author":"Mansilha","year":"2005","journal-title":"Eur J Vasc Endovasc Surg"},{"issue":"9","key":"2026101310433973900_bib62","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1161\/01.ATV.0000174806.76629.7b","article-title":"Recurrence rate after a first venous thrombosis in patients with familial thrombophilia","volume":"25","author":"Vossen","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"1","key":"2026101310433973900_bib63","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1097\/01.mbc.0000201488.33143.09","article-title":"Risk of recurrent venous thrombosis in patients with G20210A mutation in the prothrombin gene or factor V Leiden mutation","volume":"17","author":"Gonz\u00e1lez-Porras","year":"2006","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"2","key":"2026101310433973900_bib64","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.thromres.2007.03.020","article-title":"Venous thromboembolism in carriers of the Factor V Leiden mutation and in patients without known thrombophilic risk factor; prediction of recurrence and APC-PCI complex concentration and\/or soluble thrombomodulin antigen and activity","volume":"121","author":"Strandberg","year":"2007","journal-title":"Thromb Res"},{"issue":"2","key":"2026101310433973900_bib65","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3324\/haematol.10516","article-title":"The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients","volume":"92","author":"Prandoni","year":"2007","journal-title":"Haematologica"},{"issue":"5","key":"2026101310433973900_bib66","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1503\/cmaj.080493","article-title":"Identifying unprovoked thromboembolism patients at low risk for recurrence who can discontinue anticoagulant therapy","volume":"179","author":"Rodger","year":"2008","journal-title":"CMAJ"},{"issue":"3","key":"2026101310433973900_bib67","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1007\/s11239-010-0452-x","article-title":"Incidence of recurrent venous thromboembolism and of chronic thromboembolic pulmonary hypertension in patients after a first episode of pulmonary embolism","volume":"30","author":"Poli","year":"2010","journal-title":"J Thromb Thrombolysis"},{"issue":"7","key":"2026101310433973900_bib68","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/MBC.0b013e32833ceaef","article-title":"Long-term prospective study of recurrent venous thromboembolism in a Hispanic population","volume":"21","author":"Mello","year":"2010","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"25","key":"2026101310433973900_bib69","doi-asserted-by":"crossref","first-page":"2740","DOI":"10.1161\/CIRCULATIONAHA.109.927046","article-title":"Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis","volume":"121","author":"Martinelli","year":"2010","journal-title":"Circulation"},{"issue":"1","key":"2026101310433973900_bib70","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.thromres.2011.10.026","article-title":"Sex-specific risk factors for recurrent venous thromboembolism","volume":"130","author":"Oli\u00e9","year":"2012","journal-title":"Thromb Res"},{"issue":"4","key":"2026101310433973900_bib71","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1161\/CIRCULATIONAHA.113.003756","article-title":"Mild antithrombin deficiency and risk of recurrent venous thromboembolism: a prospective cohort study","volume":"129","author":"Di Minno","year":"2014","journal-title":"Circulation"},{"issue":"6","key":"2026101310433973900_bib72","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1160\/TH15-01-0031","article-title":"Plasminogen activator inhibitor-1 4G\/5G polymorphism, factor V Leiden, prothrombin mutations and the risk of VTE recurrence","volume":"114","author":"Sundquist","year":"2015","journal-title":"Thromb Haemost"},{"issue":"2","key":"2026101310433973900_bib73","doi-asserted-by":"crossref","first-page":"406","DOI":"10.1160\/th15-06-0459","article-title":"F11 is associated with recurrent VTE in women. A prospective cohort study","volume":"115","author":"Bruzelius","year":"2016","journal-title":"Thromb Haemost"},{"key":"2026101310433973900_bib74","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ejim.2015.12.010","article-title":"A risk score for prediction of recurrence in patients with unprovoked venous thromboembolism (DAMOVES)","volume":"29","author":"Franco Moreno","year":"2016","journal-title":"Eur J Intern Med"},{"issue":"19","key":"2026101310433973900_bib75","doi-asserted-by":"crossref","first-page":"2151","DOI":"10.1182\/blood-2017-09-805689","article-title":"Antiphospholipid antibodies and recurrent thrombosis after a first unprovoked venous thromboembolism","volume":"131","author":"Kearon","year":"2018","journal-title":"Blood"},{"issue":"4","key":"2026101310433973900_bib76","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1111\/jth.13960","article-title":"Mild antithrombin deficiency and risk of recurrent venous thromboembolism: results from the MEGA follow-up study","volume":"16","author":"Sokol","year":"2018","journal-title":"J Thromb Haemost"},{"issue":"4","key":"2026101310433973900_bib77","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1007\/s11239-019-01965-z","article-title":"Circumstances of provoked recurrent venous thromboembolism: the Austrian study on recurrent venous thromboembolism","volume":"49","author":"Puhr","year":"2020","journal-title":"J Thromb Thrombolysis"},{"issue":"5","key":"2026101310433973900_bib78","doi-asserted-by":"crossref","first-page":"e193690","DOI":"10.1001\/jamanetworkopen.2019.3690","article-title":"Risk and risk factors associated with recurrent venous thromboembolism following surgery in patients with history of venous thromboembolism","volume":"2","author":"Nemeth","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"6","key":"2026101310433973900_bib79","doi-asserted-by":"crossref","first-page":"874","DOI":"10.3390\/genes12060874","article-title":"Genetic risk profiling associated with recurrent unprovoked venous thromboembolism","volume":"12","author":"Hodeib","year":"2021","journal-title":"Genes (Basel)"},{"issue":"1","key":"2026101310433973900_bib80","doi-asserted-by":"crossref","first-page":"100015","DOI":"10.1016\/j.rpth.2022.100015","article-title":"Thrombophilia and outcomes of venous thromboembolism in older patients","volume":"7","author":"M\u00e9an","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"18","key":"2026101310433973900_bib81","doi-asserted-by":"crossref","first-page":"4950","DOI":"10.1182\/bloodadvances.2024012611","article-title":"Venous thromboembolism characteristics and outcomes among RIETE patients tested and untested for inherited thrombophilia","volume":"8","author":"Cohen","year":"2024","journal-title":"Blood Adv"},{"key":"2026101310433973900_bib82","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.thromres.2019.04.008","article-title":"Risk factors associated with recurrent venous thromboembolism after a first cerebral venous thrombosis event: a cohort study","volume":"178","author":"Pires","year":"2019","journal-title":"Thromb Res"},{"issue":"1-316","key":"2026101310433973900_bib83","article-title":"AS-MO-004, risk of recurrence among heterozygous carriers of factor II (FII) and a first unprovoked venous thromboembolism (VTE)","volume":"7","author":"Hron","year":"2009","journal-title":"J Thromb Haemost"},{"key":"2026101310433973900_bib84","doi-asserted-by":"crossref","first-page":"101780","DOI":"10.1016\/j.rpth.2023.101780","article-title":"PB1441 the risk of recurrent venous thromboembolism of patients with homozygous or double heterozygous factor V Leiden and\/or prothrombin G20210A mutation: a prospective cohort study","volume":"7","author":"Eischer","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"14","key":"2026101310433973900_bib85","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1093\/eurheartj\/ehac776","article-title":"Recurrent venous thromboembolism and bleeding with extended anticoagulation: the VTE-PREDICT risk score","volume":"44","author":"de Winter","year":"2023","journal-title":"Eur Heart J"},{"issue":"7","key":"2026101310433973900_bib86","doi-asserted-by":"crossref","first-page":"949","DOI":"10.7326\/M22-3559","article-title":"Indefinite anticoagulant therapy for first unprovoked venous thromboembolism : a cost-effectiveness study","volume":"176","author":"Khan","year":"2023","journal-title":"Ann Intern Med"},{"issue":"9","key":"2026101310433973900_bib87","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1016\/j.amjmed.2018.04.042","article-title":"Risk of recurrent venous thromboembolism: a Danish nationwide cohort study","volume":"131","author":"Albertsen","year":"2018","journal-title":"AJM"},{"issue":"7","key":"2026101310433973900_bib88","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1182\/bloodadvances.2018017160","article-title":"Risk of recurrent venous thromboembolism according to baseline risk factor profiles","volume":"2","author":"Prins","year":"2018","journal-title":"Blood Adv"},{"issue":"12","key":"2026101310433973900_bib89","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1016\/j.jtha.2025.08.007","article-title":"External validation of the VTE-PREDICT score for predicting recurrence and bleeding in venous thromboembolism: results from the Registro Informatizado Enfermedad TromboEmb\u1f40lica Registry","volume":"23","author":"Investigators","year":"2025","journal-title":"J Thromb Haemost"},{"issue":"3","key":"2026101310433973900_bib90","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1182\/blood-2009-08-237354","article-title":"Usefulness of repeated D-dimer testing after stopping anticoagulation for a first episode of unprovoked venous thromboembolism: the PROLONG II prospective study","volume":"115","author":"Cosmi","year":"2010","journal-title":"Blood"},{"issue":"2","key":"2026101310433973900_bib91","doi-asserted-by":"crossref","first-page":"100064","DOI":"10.1016\/j.rpth.2023.100064","article-title":"Role of factor VIII, IX, and XI in venous thrombosis recurrence risk in adults and children: a systematic review","volume":"7","author":"Bosch","year":"2023","journal-title":"Res Pract Thromb Haemost"},{"issue":"2","key":"2026101310433973900_bib92","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.thromres.2012.11.015","article-title":"Is thrombin generation at the time of an acute thromboembolic episode a predictor of recurrence? The LInk\u00f6ping Study on Thrombosis (LIST)--a 7-year follow-up","volume":"131","author":"Chaireti","year":"2013","journal-title":"Thromb Res"},{"issue":"4","key":"2026101310433973900_bib93","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jtha.2025.11.019","article-title":"Plasma proteomics does not identify biomarkers of venous thromboembolism recurrence during and after anticoagulation: results from the VISTA study","volume":"24","author":"Smit","year":"2026","journal-title":"J Thromb Haemost"},{"issue":"2","key":"2026101310433973900_bib94","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1182\/blood-2014-01-548065","article-title":"D-dimer to guide the duration of anticoagulation in patients with venous thromboembolism: a management study","volume":"124","author":"Palareti","year":"2014","journal-title":"Blood"},{"key":"2026101310433973900_bib95","doi-asserted-by":"crossref","first-page":"j1065","DOI":"10.1136\/bmj.j1065","article-title":"Validating the HERDOO2 rule to guide treatment duration for women with unprovoked venous thrombosis: multinational prospective cohort management study","volume":"356","author":"Rodger","year":"2017","journal-title":"Bmj"},{"issue":"14","key":"2026101310433973900_bib96","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1161\/CIRCULATIONAHA.109.925214","article-title":"Risk assessment of recurrence in patients with unprovoked deep vein thrombosis or pulmonary embolism: the Vienna prediction model","volume":"121","author":"Eichinger","year":"2010","journal-title":"Circulation"},{"issue":"22","key":"2026101310433973900_bib97","doi-asserted-by":"crossref","first-page":"7101","DOI":"10.1182\/bloodadvances.2023010177","article-title":"American Society of Hematology 2023 guidelines for management of venous thromboembolism: thrombophilia testing","volume":"7","author":"Middeldorp","year":"2023","journal-title":"Blood Adv"},{"issue":"6","key":"2026101310433973900_bib98","doi-asserted-by":"crossref","first-page":"e545","DOI":"10.1016\/j.chest.2021.07.055","article-title":"Antithrombotic therapy for VTE disease: second update of the CHEST guideline and expert panel report","volume":"160","author":"Stevens","year":"2021","journal-title":"Chest"},{"issue":"3","key":"2026101310433973900_bib99","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/bjh.18239","article-title":"Thrombophilia testing: a British Society for Haematology guideline","volume":"98","author":"Arachchillage","year":"2022","journal-title":"Br J Haematol"},{"issue":"3","key":"2026101310433973900_bib100","doi-asserted-by":"crossref","first-page":"e153","DOI":"10.1055\/s-0040-1714334","article-title":"Clinical utilization and cost of thrombophilia testing in patients with venous thromboembolism","volume":"4","author":"Gaddh","year":"2020","journal-title":"TH Open"},{"issue":"3","key":"2026101310433973900_bib101","doi-asserted-by":"crossref","first-page":"102864","DOI":"10.1016\/j.rpth.2025.102864","article-title":"Prevalence and factors associated with high-risk thrombophilia: a single-center cross-sectional study of 3550 patients at a tertiary Thrombosis Centre in Switzerland","volume":"9","author":"Najaf Zadeh","year":"2025","journal-title":"Res Pract Thromb Haemost"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6331\/2590303\/blooda_adv-2026-020623-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/10\/19\/6331\/2590303\/blooda_adv-2026-020623-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T14:43:53Z","timestamp":1791902633000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/10\/19\/6331\/569706\/Recurrent-VTE-in-patients-with-thrombophilia-after"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,23]]},"references-count":100,"journal-issue":{"issue":"19","published-print":{"date-parts":[[2026,10,13]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2026020623","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10,13]]},"published":{"date-parts":[[2026,9,23]]}}}